Emergent BioSolutions Inc. EBS
6.03 USD -0.02 (-0.33%)
Nov 11, 2026, 3:59 PM EST
6.00 Day range 6.12
4.36 52-week range 14.06
- YTD
- -51.21%
- 1 year
- -44.58%
News
seekingalpha.com Emergent BioSolutions: A Turnaround Still Waiting For Consistent Execution Emergent BioSolutions remains a hold as commercial recovery is uncertain despite progress on cost savings and debt reduction. EBS lowered FY26 revenue and EBITDA guidance, citing government…
benzinga.com Emergent BioSolutions Awarded $22.3M Contract Modification To Provide BioThrax To U.S. Department Of War Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a modification exercising an option period under its existing delivery order valued at up to $22.3 million to supply…
businesswire.com Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS--Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a modification exercising an option period under its existing delivery order…
benzinga.com Adeia Posts Downbeat Q3 Earnings, Joins Bioventus, Apple And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. futures mixed as Adeia plunges 23% after missing Q3 estimates and cutting FY26 guidance; Bioventus, Emergent and others also fall premarket.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Dyadic International (NASDAQ:DYAI) stock rose 13.4% to $0.43 during Tuesday's pre-market session. The market value of their outstanding shares is at $15.0 million. Aethlon Medical…
benzinga.com Why Aehr Test Systems Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket Aehr surged 15% after strong Q1 results and raised FY27 guidance; Mercer, HUB Cyber and Parabolic led gainers, while VCIG and Jaguar fell.
benzinga.com Emergent BioSolutions Q3 2026 Earnings Call Transcript Emergent BioSolutions (NYSE:EBS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com Emergent BioSolutions Lowers FY2026 Sales Guidance from $645.000M-$675.000M to $600.000M-$645.000M vs $657.133M Est Emergent BioSolutions (NYSE:EBS) lowers FY2026 sales outlook from $645.000 million-$675.000 million to $600.000 million-$645.000 million vs $657.133 million estimate.
benzinga.com Emergent BioSolutions Q3 Adj. EPS $(0.36) Beats $(0.39) Estimate, Sales $110.000M Miss $123.200M Estimate Emergent BioSolutions (NYSE:EBS) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.39) by 7.69 percent. This is a 133.96 percent decrease over earnings…
benzinga.com Novavax Shorts on Edge as Russia Plague Fears Spread Unconfirmed plague fears sent Novavax up 24% in a potential short squeeze, lifting vaccine stocks despite no clear link to its products.
benzinga.com HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $10 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $10 price target.- benzinga.com Emergent BioSolutions Receives ~$24M Contract Modification From Biomedical Advanced Research And Development Authority For Strategic Preparedness Response Within U.S. Department Of Health And Human Services To Provide CYFENDUS Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the…
benzinga.com Emergent BioSolutions Receives Canada's Offer To Provide NARCAN Nasal Spray, Effective Oct. 1 Through September 2029 Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray.…- benzinga.com World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report
benzinga.com HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $10 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $12 to $10.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…- benzinga.com Emergent BioSolutions Sees Q3 Sales $110.000M-$130.000M vs $209.000M Est Emergent BioSolutions (NYSE:EBS) sees Q3 sales of $110.000 million-$130.000 million vs $209.000 million analyst estimate.
benzinga.com Emergent BioSolutions Lowers FY2026 Sales Guidance from $720.000M-$760.000M to $645.000M-$675.000M vs $733.050M Est Emergent BioSolutions (NYSE:EBS) lowers FY2026 sales outlook from $720.000 million-$760.000 million to $645.000 million-$675.000 million vs $733.050 million estimate.- benzinga.com Emergent BioSolutions Secures $52.7M U.S. Government Contract Modification For ACAM2000 Smallpox And Mpox Vaccine Supply Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the…
benzinga.com FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose- benzinga.com Emergent BioSolutions Wins $64.5M U.S. HHS Contract Modification To Supply Botulism Antitoxin BAT Under Existing 10-Year Agreement Emergent BioSolutions Inc. (NYSE:EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response…
- benzinga.com U.S. CDC Says Will Enhance Screening And Monitoring Of Travelers Arriving From Areas Affected By Ebola Outbreaks; Will Coordinate With Airlines, Others To Manage Travelers Who May Have Already Been Exposed To Ebola; Will Enhance Contract Tracing, Hospital Readiness Nationwide https://www.cdc.gov/ebola/situation-summary/index.html
- benzinga.com Emergent BioSolutions Announces Saudi Approval For ACAM2000, Its Smallpox and Mpox Vaccine Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia)…
benzinga.com Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Emergent BioSolutions Sees Q2 Sales $170.000M-$185.000M vs $186.000M Est Emergent BioSolutions (NYSE:EBS) sees Q2 sales of $170.000 million-$185.000 million vs $186.000 million analyst estimate.- benzinga.com Emergent BioSolutions Affirms FY2026 Sales Guidance of $720.000M-$760.000M vs $735.000M Est Emergent BioSolutions (NYSE:EBS) affirms FY2026 sales outlook from $720.000 million-$760.000 million to $720.000 million-$760.000 million vs $735.000 million estimate.
- benzinga.com Emergent BioSolutions Q1 Adj. EPS $0.21 Beats $(0.25) Estimate, Sales $156.100M Beat $145.000M Estimate Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.25) by 184 percent. This is a 71.62 percent decrease over earnings of…
- benzinga.com Emergent BioSolutions Receives Singapore's Health Sciences Authority Approval For Expanded Indication For ACAM2000 Emergent BioSolutions Inc. (NYSE:EBS) today announced that Singapore's Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live)…
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com Emergent BioSolutions Signs Multi-Year, ~$50M Agreement With SAB Biotherapeutics For Development And Manufacturing Of SAB-142, SAB's Lead Program In Clinical Development For Autoimmune Type 1 Diabetes The executed agreement is valued at approximately $50 million, of which $36 million is contingent on future regulatory approval and downstream milestones.Under the terms of the agreement, Emergent…
benzinga.com Emergent BioSolutions Signs ~$34.5M Agreement With Substipharm Biologics Over Drug Substance Production For Its Japanese Encephalitis Vaccine Emergent BioSolutions Inc. (NYSE:EBS) today announced it has entered into an agreement with Substipharm Biologics valued at approximately $34.5 million to support drug substance manufacturing for its…- benzinga.com Emergent BioSolutions Collaborates With B.C. Provincial Health Services Authority To Provide Nasal Spray For Take-Home Naloxone Program Emergent BioSolutions (NYSE:EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN® Nasal Spray for the province's Take-Home Naloxone Program…
- benzinga.com Emergent BioSolutions Secures ~$54M Contract To Provide CNJ-016 Vaccinia Immune Globulin Intravenous To U. S. Department of Health And Human Services' Administration For Strategic Preparedness And Response For Smallpox Preparedness; Gets New $6.6M Incremental Orders With Undisclosed Global Federal Partner For ACAM2000 Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)]…
- benzinga.com HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $12 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $15 to $12.
benzinga.com Flutter Entertainment Posts Downbeat Q4 Results, Joins Zscaler, Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session (CORRECTED) 
benzinga.com Nasdaq Down Over 1%; Dell Shares Jump After Q4 Results U.S. stocks down mid-trading, Nasdaq falls 1%. Dow down 1.40%, S&P 500 falls 0.74%. Dell shares up 21% on Q4 earnings.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Dow Dips Over 600 Points; US Producer Prices Increase In January US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech down. Producer prices rose in January.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket 
benzinga.com Earnings Summary: Emergent BioSolutions Q4 - benzinga.com Emergent BioSolutions Sees FY2026 Sales $720.000M-$760.000M vs $1.155B Est Emergent BioSolutions (NYSE:EBS) sees FY2026 sales of $720.000 million-$760.000 million vs $1.155 billion analyst estimate.
- benzinga.com Emergent BioSolutions Q4 Adj. EPS $(0.43) Misses $0.11 Estimate, Sales $148.700M Miss $217.500M Estimate Emergent BioSolutions (NYSE:EBS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $0.11 by 490.91 percent. This is a 960 percent decrease over earnings of…
- benzinga.com Earnings Scheduled For February 26, 2026
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Emergent BioSolutions Wins FDA Approval For New Narcan Multipacks To Expand Overdose Access Emergent BioSolutions Inc. (EBS) stock rose Friday as FDA approved new multipack configurations of over-the-counter NARCAN Nasal Spray.- benzinga.com Emergent BioSolutions Obtains FDA Approval For Its Supplemental New Drug Application For New Multipack Configurations Of OTC NARCAN Nasal Spray Today, Emergent BioSolutions (NYSE:EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of…
benzinga.com Dirty Vaccines, Clean Cash: Emergent Ex-CEO Sued For Insider Trading New York Attorney General sued the former CEO of Emergent BioSolutions, Robert G. Kramer, for insider trading.